帕金森病中P2X7受体发病机制及治疗的新见解。
New insights into pathogenisis and therapies of P2X7R in Parkinson's disease.
作者信息
Wei Shizhuang, Song Xiaoyu, Mou Yakui, Yang Ting, Wang Yao, Wang Hanrui, Ren Chao, Song Xicheng
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai Yuhuangding Hospital, Yantai, China.
出版信息
NPJ Parkinsons Dis. 2025 May 5;11(1):108. doi: 10.1038/s41531-025-00980-7.
Parkinson's disease (PD), a prevalent neurodegenerative disorder, is linked to genetics and environment, but its mechanisms remain unclear. Emerging evidence connects purinergic signaling-particularly ATP-sensitive P2X7 receptor (P2X7R)-to PD. P2X7R expression is elevated in PD patients, and its antagonist BBG mitigates 6-OHDA-induced dopaminergic neuron death. This review discusses P2X7R's structure, neural functions, PD-related mechanisms, and therapeutic potential as a targert.
帕金森病（PD）是一种常见的神经退行性疾病，与遗传和环境因素有关，但其发病机制仍不清楚。越来越多的证据表明嘌呤能信号传导，特别是三磷酸腺苷敏感的P2X7受体（P2X7R）与帕金森病有关。P2X7R在帕金森病患者中的表达升高，其拮抗剂BBG可减轻6-羟基多巴胺诱导的多巴胺能神经元死亡。本文综述了P2X7R的结构、神经功能、与帕金森病相关的机制以及作为靶点的治疗潜力。
Zotero 插件